About T2 Biosystems
T2 Biosystems is a company based in Lexington (United States) founded in 2006. T2 Biosystems has raised $454.3 million across 11 funding rounds from investors including Goldman Sachs, Canon and NIH. T2 Biosystems offers products and services including Diagnostic Products. T2 Biosystems operates in a competitive market with competitors including Inflammatix, Visby Medical, MeMed, GenMark Diagnostics and Molbio Diagnostics, among others.
- Headquarter Lexington, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name T2 Biosystems, Inc.
-
Annual Revenue
$7.19 M (USD)-67.75as on Dec 31, 2023
-
Net Profit
-$50.08 M (USD)19.23as on Dec 31, 2023
-
EBITDA
-$46.29 M (USD)10.58as on Dec 31, 2023
-
Total Equity Funding
$454.3 M (USD)
in 11 rounds
-
Latest Funding Round
$2 M (USD), Grant
Mar 06, 2018
-
Investors
Goldman Sachs
& 15 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of T2 Biosystems
T2 Biosystems is a publicly listed company on the OTC with ticker symbol TTOO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of T2 Biosystems
T2 Biosystems offers a comprehensive portfolio of products and services, including Diagnostic Products.
Tools for in vitro testing in healthcare settings
People of T2 Biosystems
Unlock access to complete
Unlock access to complete
Funding Insights of T2 Biosystems
T2 Biosystems has successfully raised a total of $454.3M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $2 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in T2 Biosystems
T2 Biosystems has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, Canon and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Locked | Locked | Locked | |
|
Early-stage tech startups are funded by Flybridge Capital Partners.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for T2 Biosystems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by T2 Biosystems
Investment portfolio details for T2 Biosystems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - T2 Biosystems
Detailed financials for T2 Biosystems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
T2 Biosystems Comparisons
Peer comparison for T2 Biosystems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of T2 Biosystems
T2 Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Visby Medical, MeMed, GenMark Diagnostics and Molbio Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Point-of-care molecular platforms for infectious disease detection are developed.
|
|
| Locked | Locked | Locked |
Diagnostic technologies for infectious, cancer, and neurological diseases are developed.
|
Detailed competitors of T2 Biosystems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on T2 Biosystems
Complete news archive for T2 Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about T2 Biosystems
T2 Biosystems was founded in 2006.
T2 Biosystems is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
John Sperzel is the current CEO of T2 Biosystems.
T2 Biosystems is a funded company, having raised a total of $454.3M across 11 funding rounds to date.
Annual revenue of T2 Biosystems is $7.19M as on Dec 31, 2023.
T2 Biosystems was founded in 2006 in Lexington, United States, with operations centered in the biotechnology sector. Miniaturized magnetic resonance imaging platforms are developed for clinical diagnostics. Pathogens are detected using the proprietary T2MR technology, which measures alterations in water molecule reactions within magnetic fields. Diagnostic panels targeting bacterial septic infections, hemostasis, and Lyme disease are under development.
T2 Biosystems's top competitors include Visby Medical, Inflammatix and MeMed.
T2 Biosystems offers Diagnostic Products.
Yes, T2 Biosystems is publicly traded on OTC under the ticker symbol TTOO.
T2 Biosystems has 16 investors. Key investors include Goldman Sachs, Canon, NIH, Flagship Pioneering, and DOE.
The ticker symbol of T2 Biosystems is TTOO on OTC.